Literature DB >> 27869168

miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop.

L Shi1,2, Y Wang2, Z Lu2, H Zhang2, N Zhuang2, B Wang2, Z Song3, G Chen4, C Huang4, D Xu2,5, Y Zhang3, W Zhang1, Y Gao1.   

Abstract

The coordination between cellular differentiation and the mesenchymal/stem transition is essential for both embryo development and neoplasia, suggesting a mechanistic link between these two major processes. In this work we show that miR-127, an embryo-expressing lung miRNA, was prominently induced in lung adenocarcinoma and correlated with poor prognosis. Elevated miR-127 level drove a pronounced shift from the epithelial to the mesenchymal phenotype in cancer cells, and this shift was associated with their acquisition of stem-like traits, increased resistance to the epidermal growth factor receptor inhibitor and tumor-propagating potential. In contrast, antagonizing miR-127 markedly reversed this malignant transition, compromised the stem-like properties and the in vivo tumorigenic capability of cancer cells. Importantly, a regulatory loop involving the inflammatory signals NF-κB, miR-127 and tumor necrosis factor alpha-induced protein 3 was uncovered as a self-reinforcing circuitry that ensured an aggressive transition in lung cancer. Thus, this work identifies a novel molecular mechanism linking stemness, malignancy and inflammation, opening a new avenue for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27869168     DOI: 10.1038/onc.2016.332

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  A skin microRNA promotes differentiation by repressing 'stemness'.

Authors:  Rui Yi; Matthew N Poy; Markus Stoffel; Elaine Fuchs
Journal:  Nature       Date:  2008-03-02       Impact factor: 49.962

2.  Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.

Authors:  Kazuhiko Shien; Shinichi Toyooka; Hiromasa Yamamoto; Junichi Soh; Masaru Jida; Kelsie L Thu; Shinsuke Hashida; Yuho Maki; Eiki Ichihara; Hiroaki Asano; Kazunori Tsukuda; Nagio Takigawa; Katsuyuki Kiura; Adi F Gazdar; Wan L Lam; Shinichiro Miyoshi
Journal:  Cancer Res       Date:  2013-03-29       Impact factor: 12.701

3.  Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells.

Authors:  Philip K Lim; Sarah A Bliss; Shyam A Patel; Marcelo Taborga; Meneka A Dave; Larissa A Gregory; Steven J Greco; Margarette Bryan; Prem S Patel; Pranela Rameshwar
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

4.  A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer.

Authors:  Joaquim Calbo; Erwin van Montfort; Natalie Proost; Ellen van Drunen; H Berna Beverloo; Ralph Meuwissen; Anton Berns
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

5.  Personalized medicine and inhibition of EGFR signaling in lung cancer.

Authors:  Adi F Gazdar
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

Review 6.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

7.  MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis.

Authors:  Chi-Hong Chao; Chao-Ching Chang; Meng-Ju Wu; How-Wen Ko; Da Wang; Mien-Chie Hung; Jer-Yen Yang; Chun-Ju Chang
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

8.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

9.  Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.

Authors:  Li Li; Rui Han; Hualiang Xiao; Caiyu Lin; Yubo Wang; Hao Liu; Kunlin Li; Hengyi Chen; Fenfen Sun; Zhenzhou Yang; Jianxin Jiang; Yong He
Journal:  Clin Cancer Res       Date:  2014-03-18       Impact factor: 12.531

10.  The evolution of the DLK1-DIO3 imprinted domain in mammals.

Authors:  Carol A Edwards; Andrew J Mungall; Lucy Matthews; Edward Ryder; Dionne J Gray; Andrew J Pask; Geoffrey Shaw; Jennifer A M Graves; Jane Rogers; Ian Dunham; Marilyn B Renfree; Anne C Ferguson-Smith
Journal:  PLoS Biol       Date:  2008-06-03       Impact factor: 8.029

View more
  26 in total

1.  A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells.

Authors:  Maxine Umeh-Garcia; Catalina Simion; Pui-Yan Ho; Neelu Batra; Anastasia L Berg; Kermit L Carraway; Aiming Yu; Colleen Sweeney
Journal:  Cancer Res       Date:  2019-11-06       Impact factor: 12.701

2.  A Novel Regulatory Axis, CHD1L-MicroRNA 486-Matrix Metalloproteinase 2, Controls Spermatogonial Stem Cell Properties.

Authors:  Shan-Shan Liu; Eithne Margaret Maguire; Yin-Shan Bai; Li Huang; Yurong Liu; Liping Xu; Iliana Fauzi; Shou-Quan Zhang; Qingzhong Xiao; Ning-Fang Ma
Journal:  Mol Cell Biol       Date:  2019-02-04       Impact factor: 4.272

3.  Is MicroRNA-127 a Novel Biomarker for Acute Pancreatitis with Lung Injury?

Authors:  Na Shi; Lihui Deng; Weiwei Chen; Xiaoxin Zhang; Ruijie Luo; Tao Jin; Yun Ma; Chen Du; Ziqi Lin; Kun Jiang; Jia Guo; Xiaonan Yang; Qing Xia
Journal:  Dis Markers       Date:  2017-12-24       Impact factor: 3.434

Review 4.  Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.

Authors:  Antoine Legras; Nicolas Pécuchet; Sandrine Imbeaud; Karine Pallier; Audrey Didelot; Hélène Roussel; Laure Gibault; Elizabeth Fabre; Françoise Le Pimpec-Barthes; Pierre Laurent-Puig; Hélène Blons
Journal:  Cancers (Basel)       Date:  2017-08-03       Impact factor: 6.639

5.  Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.

Authors:  An-Fu Lee; Man-Chin Chen; Chao-Ju Chen; Chih-Jen Yang; Ming-Shyang Huang; Yu-Peng Liu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

6.  High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts.

Authors:  Jinghan Wang; Fenglin Li; Zhixin Ma; Mengxia Yu; Qi Guo; Jiansong Huang; Wenjuan Yu; Yungui Wang; Jie Jin
Journal:  EBioMedicine       Date:  2018-01-31       Impact factor: 8.143

7.  WWC3 inhibits epithelial-mesenchymal transition of lung cancer by activating Hippo-YAP signaling.

Authors:  Qiang Han; Joachim Kremerskothen; Xuyong Lin; Xiupeng Zhang; Xuezhu Rong; Di Zhang; Enhua Wang
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

Review 8.  Mechanisms of the Epithelial-Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer.

Authors:  Jacek Baj; Izabela Korona-Głowniak; Alicja Forma; Amr Maani; Elżbieta Sitarz; Mansur Rahnama-Hezavah; Elżbieta Radzikowska; Piero Portincasa
Journal:  Cells       Date:  2020-04-23       Impact factor: 6.600

9.  PMAMCA: prediction of microRNA-disease association utilizing a matrix completion approach.

Authors:  Jihwan Ha; Chihyun Park; Sanghyun Park
Journal:  BMC Syst Biol       Date:  2019-03-20

10.  A Novel Computational Method for the Identification of Potential miRNA-Disease Association Based on Symmetric Non-negative Matrix Factorization and Kronecker Regularized Least Square.

Authors:  Yan Zhao; Xing Chen; Jun Yin
Journal:  Front Genet       Date:  2018-08-21       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.